Page 124 - 《中国药房》2024年6期
P. 124

坦和阿瑞匹坦均为 NK-1 受体拮抗剂,福沙匹坦是口服                              HUANG T,GAN X M,CHEN M. Effect of aripitan com‐
          制剂阿瑞匹坦的前体药物,注射后在体内经代谢迅速转                                 bined with dexamethasone sodium phosphate and palono‐
          化为阿瑞匹坦,二者疗效相似。                                           setron in prevention of nausea and vomiting after chemo‐
              既往虽有Meta分析对不同化疗止吐方案进行评价,                             therapy  for  osteosarcoma[J].  J  Clin  Med  Pract,2020,24
          但存在纳入干预措施单一,研究数量较少,导致临床指                                (5):72-75.
                                                              [ 8 ]  SUZUKI  K,YAMANAKA  T,HASHIMOTO  H,et  al.
          导价值较低等不足。与既往Meta分析相比,本研究检索
                                                                   Randomized,double-blind,phase Ⅲ trial of palonosetron
          更充分,纳入的干预措施更全面。但本研究也存在不足
                                                                   versus  granisetron  in  the  triplet  regimen  for  preventing
          之处:(1)不同三联方案头对头比较的研究数量较少,多
                                                                   chemotherapy-induced  nausea  and  vomiting  after  highly
          通过间接比较进行效应量合并;(2)不同研究对结局事
                                                                   emetogenic  chemotherapy:triple  study[J].  Ann  Oncol,
          件的判断标准可能存在差异,无法对每个研究进行基于                                 2016,27(8):1601-1606.
          个体化水平的分析,导致结果可能存在一定偏倚。                              [ 9 ]  SUN N,ZHANG Y,LI CC,et al. Protective effect of apre‐
              综上所述,FPD较其他三联方案和二联方案防治中                              pitant against chemotherapy induced nausea and vomiting
          高度致吐风险化疗药物所致的急性CINV疗效最好。                                 in postoperative chemotherapy for gastric cancer[J].Trop J
          参考文献                                                     Pharm Res,2019,18(8):1697-1703.
          [ 1 ]  中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会                     [10]  SUGAWARA  S,INUI  N,KANEHARA  M,et  al.  Multi‐
               肿瘤支持治疗专业委员会. 中国肿瘤药物治疗相关恶心                           center, placebo-controlled, double-blind, randomized
               呕吐防治专家共识:2022 年版[J]. 中华医学杂志,2022,                   study  of  fosnetupitant  in  combination  with  palonosetron
               102(39):3080-3094.                                  for  the  prevention  of  chemotherapy-induced  nausea  and
               Professional  Committee  of  Clinical  Chemotherapy  of      vomiting in patients receiving highly emetogenic chemo‐
               Tumor  and  Specialized  Committee  on  Tumor  Support   therapy[J]. Cancer,2019,125(22):4076-4083.
               Therapy,China  Anti-cancer  Association.  Expert  consensus   [11]  Tesaro Inc. Ph3 safety/efficacy study of rolapitant for the
               on  prevention  and  treatment  of  nausea  and  vomiting         prevention  of  CINV  in  subjects  receiving  highly  emeto‐
               related to cancer drug treatment in China:2022 edition[J].   genic  chemotherapy[EB/OL].(2016-05-19)[2024-01-26].
               Natl Med J China,2022,102(39):3080-3094.            https://clinicaltrials.gov/ct2/show/study/NCT0149-9849.
          [ 2 ]  HIGGINS J P T, GREEN S. Cochrane handbook for sys‐  [12]  HELSINN  HEALTHCARE  S  A.  A  study  to  assess  the
               tematic  reviews  of  interventions  version  5.1.0[EB/OL].  safety  and  the  efficacy  of  iv  fosnetupitant/palonosetron
              (2011-03)[2024-01-26]. http://www.cochrane-handbook.org.  (260 mg/0.25 mg)combination compared to oral netupi‐
          [ 3 ]  张天嵩. Stata软件network组命令在网状Meta分析中的                 tant/palonosetron(300  mg/0.5  mg)combination  for  the
               应用[J]. 中国循证医学杂志,2015,15(11):1352-1356.              prevention  of  CINV  in  ac  chemotherapy  in  women  with
               ZHANG T S. A suite of network commands in Stata for   breast cancer[EB/OL].(2020-06-01)[2024-01-26].https://
               network meta-analysis[J]. Chin J Evid Based Med,2015,  clinicaltrials.gov/ct2/show/study/NCT03403712.
               15(11):1352-1356.                              [13]  张琳琳,白维君. 盐酸帕洛诺司琼胶囊与盐酸托烷司琼
          [ 4 ]  LI  Q  F,WU  Y,WANG  W  J,et  al.  Effectiveness  and   治疗乳腺癌术后辅助化疗引起呕吐疗效比较[J]. 临床军
               safety  of  combined  neurokinin-1  antagonist  aprepitant   医杂志,2016,44(11):1178-1180.
               treatment  for  multiple-day  anthracycline-induced  nausea   ZHANG L L,BAI W J. Palonosetron hydrochloride cap‐
               and vomiting[J]. Curr Probl Cancer,2019,43(6):100462.  sules and tropisetron hydrochloride in treatment of breast
          [ 5 ]  KIM H J,SHIN S W,SONG E K,et al. Ramosetron ver‐  cancer postoperative adjuvant chemotherapy cause vomi-
               sus ondansetron in combination with aprepitant and dexa‐  ting:curative effect comparison[J]. Clin J Med Off,2016,
               methasone  for  the  prevention  of  highly  emetogenic   44(11):1178-1180.
               chemotherapy-induced  nausea  and  vomiting:a  multi‐  [14]  谢王踢,翁洁,文芳,等. 阿瑞匹坦单药或不同止吐药物
               center,randomized phase Ⅲ trial,KCSG PC10-21[J]. On‐  联合预防顺铂化疗所致恶心、呕吐[J]. 中国新药与临床
               cologist,2015,20(12):1440-1447.                     杂志,2018,37(7):405-408.
          [ 6 ]  KANG J H,KWON J H,LEE Y G,et al. Ramosetron ver‐  XIE  W  T,WENG  J,WEN  F,et  al.  Aprepitant  mono‐
               sus palonosetron in combination with aprepitant and dexa‐  therapy or different antiemetic regimens in prevention of
               methasone  for  the  control  of  highly-emetogenic  chemo-  nausea  and  vomiting  caused  by  cisplatin[J].  Chin  J  N
               therapy-induced  nausea  and  vomiting[J].  Cancer  Res   Drugs Clin Remedies,2018,37(7):405-408.
               Treat,2020,52(3):907-916.                      [15]  LAYMAN R. Ondansetron versus palonosetron antiemetic
          [ 7 ]  黄韬,甘雪梅,陈明. 阿瑞匹坦联合地塞米松磷酸钠及盐                        regimen prior to highly emetogenic chemotherapy(HEC)
               酸帕洛诺司琼预防骨肉瘤化疗后恶心呕吐的效果[J]. 实                         [EB/OL].(2013-11-07)[2024-01-26]. https://clinicaltrials.
               用临床医药杂志,2020,24(5):72-75.                           gov/ct2/show/study/NCT01640340.


          · 754 ·    China Pharmacy  2024 Vol. 35  No. 6                               中国药房  2024年第35卷第6期
   119   120   121   122   123   124   125   126   127   128   129